The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-01-14
DOI
10.3389/fimmu.2021.799171
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LncRNA EWSAT1 Promotes Colorectal Cancer Progression Through Sponging miR-326 to Modulate FBXL20 Expression
- (2021) Jing Liu et al. OncoTargets and Therapy
- Identification of Potential Prognostic Competing Triplets in High-Grade Serous Ovarian Cancer
- (2021) Jian Zhao et al. Frontiers in Genetics
- Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
- (2021) Carmine De Angelis et al. CLINICAL CANCER RESEARCH
- Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2021) Usha Menon et al. LANCET
- Targeting Cholesterol Biosynthesis Promotes Anti-tumor Immunity by Inhibiting Long Noncoding RNA SNHG29 Mediated YAP Activation
- (2021) Wen Ni et al. MOLECULAR THERAPY
- CDK4/6 inhibition promotes anti-tumor immunity through the induction of T cell memory
- (2021) Emily J Lelliott et al. Cancer Discovery
- Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
- (2021) Colt Egelston et al. Journal for ImmunoTherapy of Cancer
- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
- (2020) Mónica Álvarez-Fernández et al. CANCER CELL
- The application and prospect of CDK4/6 inhibitors in malignant solid tumors
- (2020) Qi Du et al. Journal of Hematology & Oncology
- Circular RNA Circ_0025033 Promotes the Evolvement of Ovarian Cancer Through the Regulation of miR-330-5p/KLK4 Axis
- (2020) Hailing Cheng et al. Cancer Management and Research
- Functional determinants of cell-cycle plasticity and sensitivity to CDK4/6 inhibition
- (2020) Vishnu Kumarasamy et al. CANCER RESEARCH
- Differential regulation of cancer progression by CDK4/6 plays a central role in DNA replication and repair pathways
- (2020) Meiou Dai et al. CANCER RESEARCH
- LncRNA-SNHG29 inhibits vascular smooth muscle cell calcification by downregulating miR-200b-3p to activate the α-Klotho/FGFR1/FGF23 axis
- (2020) Chong Huang et al. CYTOKINE
- Long non-coding RNA SNHG29 regulates cell senescence via p53/p21 signaling in spontaneous preterm birth
- (2020) Jiayi Jiang et al. PLACENTA
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine
- (2019) Stephanie Lheureux et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
- (2019) Qingfei Wang et al. Nature Communications
- Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
- (2019) Mara Bonelli et al. BIOCHEMICAL PHARMACOLOGY
- BEYOND THE CELL CYCLE: ENHANCING THE IMMUNE SURVEILLANCE OF TUMORS VIA CDK4/6 INHIBITION
- (2018) Andrea C. Chaikovsky et al. MOLECULAR CANCER RESEARCH
- miR-330-5p/Tim-3 axis regulates macrophage M2 polarization and insulin resistance in diabetes mice
- (2018) Jiling Sun et al. MOLECULAR IMMUNOLOGY
- CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
- (2018) Mangala Iyengar et al. Oncotarget
- The Yet Unrealized Promise of Ovarian Cancer Screening
- (2018) Charles W. Drescher et al. JAMA Oncology
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Ovarian cancer
- (2017) Carlo La Vecchia EUROPEAN JOURNAL OF CANCER PREVENTION
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Global trends and predictions in ovarian cancer mortality
- (2016) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
- (2016) Rintaro Hashizume et al. NEURO-ONCOLOGY
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now